<a href= "https://peterattiamd.com/ama76/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=251027-pod-ama76&utm_content=251027-pod-ama76-podfeed"> View the Show Notes Page for This Episode</a> <a href= "https://peterattiamd.com/subscribe/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=251027-pod-ama76&utm_content=251027-pod-ama76-podfeed"> Become a Member to Receive Exclusive Content</a> <a href= "https://peterattiamd.com/newsletter/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=251027-pod-ama76&utm_content=251027-pod-ama76-podfeed"> Sign Up to Receive Peter’s Weekly Newsletter</a> In this “Ask Me Anything” (AMA) episode, Peter revisits the “proven, promising, fuzzy, noise, nonsense” scale and applies it to a variety of popular topics. He begins with a refresher on what each category represents before classifying a range of interventions based on the strength of their supporting evidence. The conversation spans three main areas: drugs for geroprotection (including GLP-1 receptor agonists, SGLT2 inhibitors, methylene blue, and telomere-lengthening supplements), the use of low-dose aspirin for cardiovascular disease prevention, and strategies to improve muscle mass through optimal protein intake and follistatin gene therapy. This episode provides a clear, evidence-based overview for listeners seeking to understand where these popular health and longevity interventions stand on the spectrum of scientific credibility. If you’re not a subscriber and are listening on a podcast player, you’ll only be able to hear a preview of the AMA. If you’re a subscriber, you can now listen to this full episode on your <a href= "https://peterattiamd.com/members/private-podcast-feed/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=251027-pod-ama76&utm_content=251027-pod-ama76-podfeed">private RSS feed </a>or our website at the <a href= "http://peterattiamd.com/ama75/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=251027-pod-ama76&utm_content=251027-pod-ama76-podfeed">AMA #76 show notes page</a>. If you are not a subscriber, you can learn more about the subscriber benefits <a href= "https://peterattiamd.com/subscribe/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=251027-pod-ama75&utm_content=251027-pod-ama75-podfeed">here</a>. We discuss: <ul type="disc"> <li>A scale for evaluating scientific claims: proven, promising, fuzzy, noise, or nonsense [1:30];</li> <li>Strong convictions, loosely held: the mindset that separates great scientists from the rest [7:30];</li> <li>GLP-1 receptor agonists: are there benefits beyond improving metabolic health and promoting weight loss? [12:45];</li> <li>GLP-1 drugs and the brain: exploring the potential cognitive benefits [18:45];</li> <li>GLP-1 drugs and lifespan: examining the evidence for potential geroprotective effects [23:00];</li> <li>Rapamycin and geroprotection: why it remains in the “promising” category [25:45];</li> <li>SGLT2 inhibitors and their potential geroprotective effect [27:30];</li> <li>Methylene blue: examining the evidence of an anti-aging effect [34:45];</li> <li>Methylene blue’s potential neuroprotective effects: limited and inconsistent evidence in humans, and the challenges of dosing and safety [41:15];</li> <li>Telomeres: what they are, how they relate to aging, and why telomere-lengthening supplements lack credible scientific evidence [43:45];</li> <li>Does the idea of targeting telomere length to extend lifespan have scientific merit? [50:15];</li> <li>Low-dose aspirin for cardiovascular disease prevention: weighing its clot-prevention benefits against bleeding risks across different populations [55:00];</li> <li>Rethinking the protein RDA: why most people need twice the recommended amount for muscle health [1:00:45];</li> <li>Debunking the protein–cancer myth: why higher protein intake doesn’t promote tumor growth [1:06:15];</li> <li>The biology of follistatin and myostatin, and why follistatin gene therapy has become an emerging topic of interest for muscle growth [1:13:15];</li> <li>Follistatin gene therapy for muscle growth: state of the evidence in animals and humans, and the technical challenges and regulatory barriers [1:17:00];</li> <li>Why injectable follistatin is theoretically possible but impractical for real-world use [1:23:15]; and</li> <li>More.</li> </ul> Connect With Peter on <a href= "https://twitter.com/PeterAttiaMD">Twitter</a>, <a href= "https://www.instagram.com/peterattiamd/">Instagram</a>, <a href="https://www.facebook.com/peterattiamd/">Facebook</a> and <a href="https://www.youtube.com/channel/UC8kGsMa0LygSX9nkBcBH1Sg">YouTube</a>

#370 - AMA #76: Peter evaluates longevity drugs, aspirin for CVD, and strategies to improve muscle mass — promising, proven, fuzzy, noise, or nonsense?

Podurama

Home

Trending

Personal

Your Podcasts

New Episodes

My Files

Favourite Episodes

Tags (Folders)

Recently Played

Bookmarks

Followed Playlists

#370 - AMA #76: Peter evaluates longevity drugs, aspirin for CVD, and strategies to improve muscle mass — promising, proven, fuzzy, noise, or nonsense?

The Peter Attia Drive

AI Chapters

AI Insights

Reviews